News

Fulvestrant bests anastrozole in advanced breast cancer

Publish date: December 18, 2014

 

AT SABCS 2014

References

The FIRST trial was funded by AstraZeneca. Dr. Robertson reported serving as a consultant to that company as well as Bayer HealthCare and receiving research funding from both companies along with Amgen and Novartis.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

SOFT trial endorses selective ovarian suppression in early breast cancer
Breast Cancer ICYMI
VIDEO: Dr. Prudence Francis describes how SOFT results will change practice
Breast Cancer ICYMI
VIDEO: What was the most interesting thing you learned at the meeting?
Breast Cancer ICYMI
20 years after initiating preventive tamoxifen, less breast cancer but no survival benefit
Breast Cancer ICYMI
VIDEO: What have we learned about prevention of breast cancer from IBIS-1?
Breast Cancer ICYMI
AI-induced symptoms don’t predict survival
Breast Cancer ICYMI
Acupuncture beats gabapentin for hot flashes in RCT
Breast Cancer ICYMI
Genetic test predicts 10-year risk of DCIS recurrence
Breast Cancer ICYMI
Information and communication needs of Chinese American breast cancer patients: perspectives on survivorship care planning
Breast Cancer ICYMI
Predictors of resolution in navigated patients with abnormal cancer screening tests
Breast Cancer ICYMI